Pfizer Covid Shot Safely Bolsters Antibodies in Younger Kids

during a vaccination event at a school in Boston, Massachusetts, U.S., on Monday, August 16, 2021. With the highly contagious Delta variant sending more children to hospitals, a dozen states now require K-12 students to wear masks, while another handful bar such mandates.

(Bloomberg) --Pfizer Inc. and partner BioNTech SE said their Covid-19 vaccine was safe and produced strong antibody responses in children ages 5 to 11 in a large-scale trial, findings that could pave the way to begin vaccinating grade-school kids within months.

By Robert Langreth
Sep 20, 2021, 12:45 PM – Updated on Sep 20, 2021, 1:17 PM
Word Count: 649
The long-awaited results offer one of the first looks at how well a Covid vaccine could work for younger children. Pressure to immunize kids has been on the climb in the U.S., where a new school year has started just as the delta variant is fueling a surge in cases.

In a trial with 2,268 participants, two shots of a 10 microgram dose — one-third the adult shot — produced antibody levels comparable to those seen in a trial of 16-to-25-year-olds who got the adult dose, the companies said, with similar side effects.

Play Video
Pfizer and BioNTech said they plan to submit the data as part of a near-term request for an emergency-use authorization from the U.S. Food and Drug Administration, and to share it with regulators in Europe as well.

Read More: Vaccine Mandates for Kids Are the Next Big Fight for Schools

A clearance would mark an important new phase of the immunization campaign in the U.S., where the Pfizer vaccine already has full approval for people 16 and up and is authorized on an emergency basis for ages 12 to 15. And a pediatric clearance could arrive as millions of older Americans are receiving additional doses to bolster their initial shots.

Pfizer shares pared losses early Monday, falling 1.1% as of 7:11 a.m. in premarket trading in New York. BioNTech’s U.S. shares fell 4.1%

The FDA is expected to decide whether to allow a booster shot for the Pfizer-BioNTech vaccine within days. On Friday, an advisory panel unanimously backed a third dose for people 65 and over, as well as those at high risk of severe complications, after voting against Pfizer’s request to authorize boosters for everyone 16 and older.

While the FDA often follows its advisers, it isn’t obliged to, and could still opt to support boosters for a bigger group. Only certain immunocomprised people are now officially permitted to get a third dose on an emergency basis.

Initial data from other arms of the Pfizer-BioNTech pediatric trial, testing the vaccine in children under 5, could come in the fourth quarter, the companies said.

Bigger Trial
The data on kids from 5 to 11 was from an initial tranche of patients in the trial. At the request of U.S. regulators, Pfizer and BioNTech have submitted a plan to add 2,250 more children between the ages of 5 and 11 to their pediatric studies, a Pfizer spokesman said in an email.

In an interview with Bloomberg News this summer, top FDA vaccine official Peter Marks said he asked drugmakers to expand their pediatric trials three or four times in size “to try to have a larger safety dataset” to increase confidence in the shots.

Safety is a crucial metric for young kids, as they get infected frequently and help spread the virus, but are at lower risk of developing severe complications than older adults. In rare cases, the messenger RNA vaccines have been linked to heart inflammation and heart-lining inflammation, and the risk appears to be highest in younger males.

The companies didn’t give specific side effect numbers in the release. Pfizer and BioNTech also didn’t say whether kids who got the vaccine had lower rates of Covid illness compared with those who got a placebo, data that the trial planned to collect as a secondary goal.

A spokesman for Pfizer said the trial is still ongoing and some data is still blinded. In the statement, the companies said they planned to submit the full data from the trial for publication in a scientific journal.

(Updates with share trading in sixth paragraph.)
© 2021 Bloomberg L.P.


Comments - Please in order to comment.

Please peer review 3 community comments before your comment can be posted

[%% img-description %%]

The Spy Bill: An autocratic roadmap to State Capture 2.0

Join Heidi Swart in conversation with Anton Harber and Marianne Merten as they discuss a concerning push to pass a controversial “Spy Bill” into law by May 2024. Tues 5 Dec at 12pm, live, online and free of charge.

A South African Hero: You

There’s a 99.8% chance that this isn’t for you. Only 0.2% of our readers have responded to this call for action.

Those 0.2% of our readers are our hidden heroes, who are fuelling our work and impacting the lives of every South African in doing so. They’re the people who contribute to keep Daily Maverick free for all, including you.

The equation is quite simple: the more members we have, the more reporting and investigations we can do, and the greater the impact on the country.

Be part of that 0.2%. Be a Maverick. Be a Maverick Insider.

Support Daily Maverick→
Payment options